Hiroshi Ueno
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (22)
Year:
2026
Background Preprocedural screening using transesophageal echocardiography (TEE) and computed tomography (CT) is widely performed in patients undergoing left atrial appendage (LAA) closure (LAAC). However, established methods for accurately predicting procedural device success (DS) remain unclear. Aims This study aimed to evaluate whether a novel preprocedural CT‐based assessment focusing on the landing zone and presence of an internal septum could improve DS prediction. Methods We analyzed 560 patients from a Japanese multicenter registry who underwent LAAC with Watchman FLX (Boston Scientific, USA). Preprocedural CT multiplanar reconstruction measured the diameter of the LAA landing zone (Dland), LAA length (L), and major lobe ostium diameter (Dlobe), if present. Based on these measurements, a ratio calculation (Rcal), defined as L/(Dland−Dlobe), was used to predict DS. The predictive performance of this ratio was evaluated using receiver operating characteristic (ROC) curve analysis and compared with that of conventional CT‐ and TEE‐derived depth‐to‐ostium ratios. Results DS was achieved in 95.5% (535/560) of patients. The mean Rcal was significantly lower in the failure group than in the success group (0.66 ± 0.25 vs. 1.00 ± 0.28; p < 0.001). Rcal predicted DS with an area under the ROC curve (AUC) of 0.872 ( p < 0.001). An optimal Rcal cutoff of 0.77 demonstrated 80.0% sensitivity and 83.4% specificity. Rcal showed superior predictive performance compared with CT depth/ostium ratio (AUC: 0.552) and TEE depth/ostium ratio (AUC: 0.456). Conclusions The novel CT‐derived metric, Rcal, which accounts for LAA landing zone dimensions and internal septa, predicts the DS of Watchman FLX. Rcal may improve pre‐LAAC patient selection and procedural planning.
Year:
2026
Background Given the relatively high morbidity and death associated with transcatheter edge‐to‐edge repair for secondary mitral regurgitation, the development of optimal risk stratification models is imperative. The J‐MACS (Japanese Registry for Mechanically Assisted Circulatory Support) score is a recently developed tool designed to stratify risk in patients with advanced heart failure undergoing durable left ventricular assist device implantation. Methods Data were obtained from the OCEAN‐Mitral (Optimized Catheter Valvular Intervention–Mitral) registry on patients with secondary mitral regurgitation and left ventricular ejection fraction <50% who underwent transcatheter edge‐to‐edge repair. A newly innovated modified J‐MACS score, incorporating age, history of cardiac surgery, serum creatinine levels, and postprocedural moderate or greater tricuspid regurgitation, was calculated. Its prognostic significance regarding the primary outcome, comprising all‐cause death and heart failure–related hospitalizations, was assessed. Results A total of 2006 patients (median age, 77 years; 63% men) were included in the study. The median modified J‐MACS score was 13.7 (interquartile range, 12.0–16.2). Based on statistically calculated optimal cutoff values of 11.4 and 14.0, patients were stratified into 3 risk categories: low, moderate, and high. The 2‐year cumulative incidence of the primary outcome differed significantly among these groups (26%, 37%, and 51%, respectively; P <0.001). Risk group classification remained independently associated with the primary outcome, with an adjusted hazard ratio of 1.42 (95% CI, 1.13–1.71; P <0.001) for the intermediate risk versus low risk and 2.27 (95% CI, 1.67–2.96; P <0.001) for the high risk versus low risk. Conclusions The modified J‐MACS score demonstrated an independent association with all‐cause death and heart failure–related hospitalization following transcatheter edge‐to‐edge repair in patients with significant mitral regurgitation and systolic heart failure. Registration URL: https://upload.umin.ac.jp ; Unique Identifier: UMIN000023653.
Year:
2025
Background Transcatheter edge‐to‐edge repair of the mitral valve (M‐TEER) has demonstrated promising outcomes for patients with mitral regurgitation who are unsuitable for surgical intervention. However, the clinical implications of M‐TEER in patients requiring mechanical circulatory support (MCS) for unstable hemodynamics remains unclear. This study aimed to evaluate the outcomes of MCS‐assisted M‐TEER in critically ill patients. Methods Consecutive patients who underwent M‐TEER for significant mitral regurgitation were identified from the Japanese multicenter OCEAN‐Mitral (Optimized Catheter Valvular Intervention–Mitral) registry. All‐cause death was compared between the cohort undergoing MCS‐assisted M‐TEER and a virtual control group receiving MCS alone without undergoing M‐TEER, estimated using the Seattle Heart Failure Model. Additionally, logistic regression analysis was conducted to identify factors associated with in‐hospital death following MCS‐assisted M‐TEER. Results A total of 3764 patients were included in the analysis (mean age, 81 years; 54.9% men; 70.1% with secondary mitral regurgitation), of whom 105 underwent MCS‐assisted M‐TEER. Procedure success exceeded 95%, irrespective of MCS use. The 1‐year mortality rate in the MCS‐assisted M‐TEER group was lower than the estimated mortality rate in the virtual control group (43.2% versus 69.5%). Factors associated with in‐hospital death included frailty, inflammation, and hypoalbuminemia. In a landmark analysis starting from discharge date, there was no statistically significant difference in cardiovascular death or heart failure hospitalization between the groups with or without the use of MCS (hazard ratio, 1.45 [95% CI, 0.93–2.26]; P =0.10). Conclusions MCS‐assisted M‐TEER appears to be a viable and effective therapeutic strategy for carefully selected patients with significant mitral regurgitation and unstable hemodynamics. Registration URL: https://www.umin.ac.jp/ctr/ ; Unique identifier: UMIN‐ID: UMIN000023653
Year:
2025
Background Anticoagulants are often less frequently prescribed in elderly patients with atrial fibrillation (AF) because of concerns regarding high bleeding risk, despite their increased susceptibility to embolic stroke and systemic embolization. This study evaluated the impact of the Clinical Frailty Scale (CFS) on clinical outcomes and decision-making for prescribing antithrombotic therapy following left atrial appendage closure (LAAC) in a large contemporary registry. Methods The OCEAN-LAAC registry included 1,409 patients who underwent LAAC. Outcomes and antithrombotic prescriptions after the procedure were compared between groups stratified by CFS into 1–3 and 4–8. Results Patients with CFS 4–8 were more likely to have a history of stroke and demonstrated lower serum albumin and hemoglobin levels, consistent with advanced frailty. In multivariate analysis, CFS 4–8 was independently associated with higher all-cause mortality at one year compared with CFS 1–3 (adjusted hazard ratio 1.89; 95% confidence interval 1.05–3.41). By one year, patients with CFS 4–8 more frequently discontinued antithrombotic therapy, without significant differences in ischemic stroke or device-related thrombotic events. Notably, major bleeding was more common in the CFS 4–8 group, reflecting their advanced clinical vulnerability. Conclusion Greater frailty, as assessed by CFS, was independently associated with increased all-cause mortality following LAAC. Although frailty influenced patterns of antithrombotic therapy in this real-world registry, thrombotic events remained comparable between CFS groups, supporting the feasibility of individualized, frailty-guided post-LAAC management. These findings underscore the importance of incorporating frailty assessment into multidisciplinary Brain–Heart team decision-making.
Year:
2025
Background The management of very low‐gradient (LG) severe aortic stenosis (AS) remains challenging. Moreover, limited evidence exists regarding the outcomes of patients with very LG severe AS following transcatheter aortic valve implantation (TAVI). Aims We aimed to elucidate the prognosis of patients with very LG severe AS after TAVI and the influence of flow status. Methods Data were retrospectively collected from the OCEAN‐TAVI multicenter registry in Japan, including patients with severe AS who underwent TAVI. Results In total, 7103 patients were classified into three groups based on their baseline mean pressure gradient (MPG): very LG (MPG ≤ 20 mmHg), LG (20 < MPG < 40 mmHg), and high‐gradient (HG) (MPG ≥ 40 mmHg). The primary endpoint was a composite of all‐cause mortality and hospitalization for heart failure. During a median follow‐up period of 741 days, the composite endpoint was reached in 2081 patients. Patients with very LG severe AS had a higher prevalence of comorbidities. Kaplan–Meier analysis showed that very LG severe AS was associated with significantly lower event‐free survival compared to that with LG and HG severe AS. Multivariable Cox regression analysis identified very LG severe AS as an independent poor prognostic indicator, regardless of the flow state. Moreover, within the very LG severe AS group, a low body mass index and myocardial infarction history were associated with worse outcomes. Conclusion This study indicates that patients with very LG severe AS have worse prognoses compared to those with LG or HG severe AS following TAVI, regardless of the flow state.
Year:
2025
Background One‐year clinical and hemodynamic outcomes after transcatheter aortic valve replacement (TAVR) using the latest generation balloon‐expandable valve (BEV) and self‐expandable valve (SEV) is not well understood. This study is aimed to compare 1‐year morality and hemodynamics between the latest generation BEV and SEV after TAVR. Methods We retrospectively analyzed 1393 patients undergoing TAVR using BEV (63.7%) (SAPIEN3 Ultra RESILIA) and SEV (36.3%) (Evolut FX). The incidence of all‐cause mortality and bioprosthetic valve dysfunction (BVD) over 1‐year were compared between BEV and SEV in both overall and propensity score (PS) matched cohort. Results During 1‐year follow‐up, the incidence of all‐cause mortality was comparable between BEV and SEV in the overall (10.8% vs. 8.0%, log‐rank p = 0.30) and PS matched cohort (11.0% vs. 8.9%, log‐rank p = 0.40). The incidence of BVD through 1‐year was also comparable between BEV and SEV in the overall (6.2% vs. 6.9%, p = 0.59) and PS matched cohort (6.7% vs. 8.2%, p = 0.55). Of BVD component, post‐procedural mean pressure gradient more than 20mmH was higher in BEV, while para‐valvular leakage more than moderate was higher in SEV. There was non‐linear relationship between annulus size and BVD, in which TAVR with BEV had higher BVD in a small annulus, while SEV had higher BVD in a large annulus. Conclusions In TAVR using the latest generation valves, incidences of mortality and valve performance during 1‐year were comparable between BEV and SEV. Whereas, the impact of annulus size on the difference of valve hemodynamics between BEV and SEV is still observed.
Year:
2025
Background The association of outcomes with initial clip selection has not been investigated in patients undergoing transcatheter edge‐to‐edge repair with the MitraClip G4. Methods We analyzed 2257 patients receiving the MitraClip G4 according to the initial clip type: short (NT/NTW) versus long (XT/XTW) and narrow (NT/XT) versus wide (NTW/XTW). We performed a propensity‐matched analysis of baseline anatomical features in patients with primary and secondary mitral regurgitation (MR). Results The proportions of the initial clip types were as follows: NT, 18.9%; NTW, 41.7%; XT, 5.1%; and XTW, 34.3%. The proportions of the MR severity ≤1+ at discharge and 1 year were not significantly different among the 4 clip types. The incidence of death or heart failure hospitalization was not significantly different between the initial long and short clip groups and between the initial wide and narrow clip groups. After propensity matching, in patients with primary MR, long clips were significantly associated with a greater MR reduction (2.87±0.89 versus 2.62±0.99, P =0.04) and a higher proportion of the MR severity ≤1+ at 1 year (68.2% versus 48.6%, P =0.04) than short clips. In patients with secondary MR, long or wide clips had a similar MR severity at discharge and 1 year as short or narrow clips. Conclusions Residual MR severity and outcomes were not different regardless of the initial clip type, indicating the optimal clip selection in the real‐world settings with the MitraClip G4. In patients with primary MR, greater and more durable MR reduction may be expected by using the initial long clips. Registration URL: https://www.umin.ac.jp/ctr/ ; Unique identifier: UMIN‐ID: UMIN000023653.
Year:
2025
Background Low serum albumin levels indicate frailty and are strong predictors of poor prognosis after mitral transcatheter edge‐to‐edge repair (M‐TEER); however, albumin levels are expected to improve in response to treatment for mitral regurgitation. No reports have elucidated the clinical effects of albumin changes after M‐TEER. Thus, we aimed to explore the association between early albumin changes and clinical outcomes after M‐TEER and to identify the associated factors. Methods Data from 2695 patients enrolled in a Japanese multicenter registry whose serum albumin levels were measured before and 1 month after undergoing M‐TEER were retrospectively reviewed. Changes in albumin (Δ‐albumin) were calculated and divided into 2 groups, namely improved albumin (Δ‐albumin >0) and worsening albumin (Δ‐albumin ≤0) groups. The incidence, predictors, and clinical outcomes associated with early albumin changes were investigated. Results After M‐TEER, albumin levels improved in 56.1% of the patients (n=1512). The independent predictors of worsening Δ‐albumin comprised old age, acute procedure success not achieved, higher Clinical Frailty Scale, higher hemoglobin, impaired renal function, and preprocedural higher albumin levels (all P <0.05). Improved Δ‐albumin was independently associated with reduced all‐cause mortality after M‐TEER (hazard ratio [HR], 0.62 [95% CI, 0.52–0.75], P <0.001). Additionally, improved Δ‐albumin was associated with a lower competing risk of heart failure hospitalization (HR, 0.78 [95% CI, 0.64–0.94], P =0.01). Conclusions Early improvement in Δ‐albumin may serve as a measure of procedural benefits and a surrogate marker for predicting clinical outcomes after M‐TEER.
Year:
2025
Background: Percutaneous left atrial appendage closure (LAAC) reduces the incidence of stroke/bleeding events in patients with non-valvular atrial fibrillation, high risk of stroke, and contraindication in continuing anticoagulation therapy. Of them, patients with heart failure may remain at high risk of these events after LAAC. Method: Patients who underwent LAAC and were listed for the multi-center, prospectively collected OCEAN-LAAC registry, were eligible. Of them, individuals without baseline plasma B-type natriuretic peptide (BNP) levels and those dependent on hemodialysis were excluded. The prognostic impact of baseline plasma BNP levels on the incidence of death or stroke/bleeding events after LAAC was evaluated. Results: A total of 937 patients (median 78 years, 596 men) were included. The LAAC device was successfully implanted in 934 (98%) patients. Over the 366 (251, 436) days after the LAAC, 148 patients encountered a primary outcome. The common logarithm of baseline plasma BNP was independently associated with the primary outcome with an adjusted hazard ratio of 1.46 (95% confidence interval 1.06–2.18, p = 0.043). A calculated cutoff of 2.12 (equivalent to 133 pg/mL of plasma BNP level) significantly stratified the cumulative incidence of the primary outcome (29% vs. 21% for 2 years, p = 0.004). Conclusions: Using prospectively collected large-scale multi-center Japanese registry data, we demonstrated that a baseline higher plasma BNP level was independently associated with a higher incidence of stroke/bleeding events and mortality after LAAC. Further studies are warranted to understand the optimal therapeutic strategy for LAAC candidates with elevated baseline plasma BNP levels.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (5)
Kentaro Hayashida
Keio University School of Medicine
Gaku Nakazawa
Kindai University Hospital
Teruhiko Imamura
University of Toyama
Yusuke Watanabe
Teikyo University Hospital
Shuhei Tanaka
University of Toyama
Make your next move.
Prepare your application
Review drafts before you send them.